Mind Cure Health News

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

10.08.21	MINDCURE Welcomes Dr. Ken Weingardt, Digital Therapy Visionary, as a Senior Clinical Technology Advisor to its Psychedelic Digital Therapeutics Team (PR Newswire)
10.08.21	MINDCURE Welcomes Dr. Ken Weingardt, Digital Therapy Visionary, as a Senior Clinical Technology Advisor to its Psychedelic Digital Therapeutics Team (PR Newswire)
04.08.21	MINDCURE Appoints Jerry White, Award-Winning Humanitarian Activist Who Shares in the 1997 Nobel Peace Prize, as Company Advisor (PR Newswire)
04.08.21	MINDCURE Appoints Jerry White, Award-Winning Humanitarian Activist Who Shares in the 1997 Nobel Peace Prize, as Company Advisor (PR Newswire)
27.07.21	MINDCURE Launches Second Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research (PR Newswire)
27.07.21	MINDCURE Launches Second Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research (PR Newswire)
13.07.21	MINDCURE Announces Filing of U.S. Provisional Patent Applications for Company's First Fully Synthetic Routes to Create an Ibogaine Psychedelic Compound (PR Newswire)
13.07.21	MINDCURE Announces Filing of U.S. Provisional Patent Applications for Company's First Fully Synthetic Routes to Create an Ibogaine Psychedelic Compound (PR Newswire)
12.07.21	MINDCURE Adopts Advance Notice Policy (PR Newswire)
12.07.21	MINDCURE Adopts Advance Notice Policy (PR Newswire)
30.06.21	Maxim Group Initiates Coverage of Mind Cure Health (PR Newswire)
17.06.21	MINDCURE Develops Proprietary Ketamine-Enhanced Psychotherapy Protocols for Treatment of Pain and Depression (PR Newswire)
17.06.21	MINDCURE Develops Proprietary Ketamine-Enhanced Psychotherapy Protocols for Treatment of Pain and Depression (PR Newswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

CieFinRichemont	121.15	2.19 %	K V
Logitech Intl	72.20	1.66 %	K V
Lonza Grp	526.60	1.00 %	K V
Swiss Re	129.35	0.82 %	K V
UBS Group	28.35	0.18 %	K V
Givaudan	3’901.00	-0.81 %	K V
Swiss Life Hldg	725.40	-1.12 %	K V
Holcim	89.78	-1.12 %	K V
Novartis	91.93	-1.87 %	K V
Sonova Hldg	306.20	-1.89 %	K V